STOCK TITAN

Patrick Finn of Twist Bioscience (TWST) files to sell 3,500 shares under Rule 144

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Patrick Finn filed a notice to sell up to 3,500 shares of Twist Bioscience common stock under Rule 144. The filing lists an aggregate market value of 175,789.00 for these shares, to be sold through Fidelity Brokerage Services LLC on NASDAQ.

The shares come from option grants dated 11/19/2018 and 10/24/2019 totaling 2,500 shares, and 1,000 shares from restricted stock vesting on 11/08/2024. Recent activity also shows separate sales, including 23,279 shares on 01/13/2026 for gross proceeds of 931,160.00.

Positive

  • None.

Negative

  • None.

Insights

Routine Rule 144 filing for planned insider share sales.

The notice shows Patrick Finn planning to sell up to 3,500 shares of Twist Bioscience common stock under Rule 144, with an aggregate market value of 175,789.00. The shares come from option exercises and restricted stock vesting, which are common sources of insider liquidity.

The document also details several prior sales in the last three months, including 23,279 shares sold on 01/13/2026 for gross proceeds of 931,160.00. This pattern suggests ongoing diversification rather than a discrete corporate event. Overall, this appears to be a standard insider selling program rather than a thesis-changing development.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filing for TWST’s Patrick Finn disclose?

The filing discloses that Patrick Finn plans to sell up to 3,500 shares of Twist Bioscience common stock. The shares have an aggregate market value of 175,789.00 and will be sold on NASDAQ through Fidelity Brokerage Services LLC under Rule 144.

How many Twist Bioscience (TWST) shares is Patrick Finn planning to sell?

Patrick Finn’s notice covers up to 3,500 Twist Bioscience common shares. The filing states an aggregate market value of 175,789.00 for these shares, to be transacted through Fidelity Brokerage Services LLC on NASDAQ, subject to Rule 144 conditions and market execution.

What is the source of the TWST shares Patrick Finn plans to sell?

The shares come from option grants and restricted stock vesting. The filing lists 1,500 shares from an option granted 11/19/2018, 1,000 from an option granted 10/24/2019, and 1,000 from restricted stock that vested on 11/08/2024, totaling 3,500 shares.

What recent TWST share sales by Patrick Finn are reported in the filing?

The filing lists several recent sales, including 1,776 shares on 11/21/2025, 23,279 shares on 01/13/2026, 2,390 shares on 01/23/2026, and 2,705 shares on 02/03/2026. Gross proceeds range from 47,070.22 to 931,160.00, showing substantial recent selling activity.

On which exchange will the TWST shares in Patrick Finn’s Form 144 be sold?

The notice specifies that the 3,500 Twist Bioscience common shares are expected to be sold on NASDAQ. Fidelity Brokerage Services LLC is listed as the broker, and the filing associates an aggregate market value of 175,789.00 with the planned sales under Rule 144.

What representation does Patrick Finn make in the TWST Form 144 filing?

By signing the notice, Patrick Finn represents that he does not know any material adverse information about Twist Bioscience’s current or prospective operations that has not been publicly disclosed, as required in the standard Rule 144 form language for such planned sales.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

3.01B
87.68M
Diagnostics & Research
Biological Products, (no Diagnostic Substances)
Link
United States
SOUTH SAN FRANCISCO